Lymphoma is a cancer of a part of the immune system called the lymphatic system. There are many types of lymphoma. One type is Hodgkin disease, and the other types are called non-Hodgkin lymphoma.
Programs + Services
Explore our blood cancer program and learn more about treatment options for hematologic malignancies including lymphoma and leukemia at Tufts Medical Center in Boston.
Research + Clinical Trials
In step 1, to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on lymphoma compared to rituximab plus bendamustine alone.
In step 2, to find out what effects, good and bad, continuing chemotherapy after step 1 with lenalidomide plus rituximab has on lymphoma compared to continuing chemotherapy with rituximab alone.
This study involves administration of an investigational drug called SGN35 (brentuximab vedotin) in combination with standard chemotherapy (adriamycin, vinblastine, and dacarbazine, or AVD) for participants 60 years old or older with untreated Hodgkin Lympoma
The primary purpose of this study is to evaluate the safety of the combination of two different drugs (brentuximab vedotin and rituximab) in patients with certain types of lymphoma. This study is for patients who have a type of lymphoma that expresses a tumor marker called CD30 and/or a type that is associated with the Epstein-Barr virus (EBV-related lymphoma) and who have not yet received any treatment for their cancer, except for dose-reduction or discontinuation (stoppage) of medications used to prevent rejection of transplanted organs (for those patients who have undergone transplantation). These include, but are not limited to, diffuse large B-cell lymphoma (DLBCL), post-transplant lymphoproliferative disorder (PTLD), non-Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma (HL), and peripheral T-cell lymphoma (PTCL). In addition, this study will attempt to evaluate how effective this combination of study drugs may be in addressing these types of lymphoma.
The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP) has on you and your cancer. Everybody in this study will receive standard chemotherapy. In addition to standard chemotherapy randomly chosen half of the subjects will receive a medication called lenalidomide. Adding lenalidomide to the standard chemotherapy RCHOP is considered experimental in diffuse large B cell lymphoma, and is not FDA approved. There is NO placebo (“sugar pill”) in this study, and everybody selected will receive an active medication.